A Multicenter, Open-label Study To Evaluate The Long-term Safety, Tolerability And Efficacy Of Subcutaneous Or Intravenous Pf-06741086 In Subjects With Severe Hemophilia
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Marstacimab (Primary) ; Marstacimab (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions
- Sponsors Pfizer
- 30 Mar 2018 Planned End Date changed from 12 Jun 2019 to 1 Jul 2019.
- 30 Mar 2018 Planned primary completion date changed from 12 Jun 2019 to 1 Jul 2019.
- 30 Mar 2018 Planned initiation date changed from 21 Mar 2018 to 1 May 2018.